Oxybutynin

Generic Name: Oxybutynin

Brand Names: Ditropan, Gelnique, Kentera, Oxytrol, Kentera (previously Oxybutynin Nicobrand)

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₁NO_₃

CAS Number: 5633-20-5

Unique Ingredient Identifier: K9P6MC7092

Background: Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.
...

Indication: Oxybutynin is indicated for the symptomatic treatment of overactive bladder, which causes urge urinary incontinence and frequency, and urgency. Oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition. Spina bifida is an example of a...

Associated Conditions: Bladder Spasms, Detrusor Hyperreflexia, Overactive Bladder Syndrome (OABS)

Associated Therapies: -

Clinical Trials

Effect of Heat on Oxybutynin Release and Absorption From Oxybutynin Products

Early Phase 1

Completed

Conditions: Heat Effect

Interventions: Drug: oxybutynin

First Posted Date: 2017-07-02

Last Posted Date: 2022-04-11

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 13

Registration Number: NCT03205605

Locations: 🇺🇸
General Clinical Research Center (GCRC) at the University of Maryland Medical Center, Baltimore, Maryland, United States

The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.

Not Applicable

Completed

Conditions: Hyperhidrosis

Interventions: Drug: Oxybutynin
Drug: Placebos

First Posted Date: 2016-11-25

Last Posted Date: 2016-11-25

Lead Sponsor: Tel-Aviv Sourasky Medical Center

Target Recruit Count: 61

Registration Number: NCT02973659

Oxybutynin Chloride in Managing Hot Flashes

Phase 3

Completed

Conditions: Breast Carcinoma
Ductal Breast Carcinoma In Situ
Hot Flashes
No Evidence of Disease
Lobular Breast Carcinoma In Situ

Interventions: Other: Placebo
Drug: Oxybutynin Chloride
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2016-11-11

Last Posted Date: 2020-01-18

Lead Sponsor: Academic and Community Cancer Research United

Target Recruit Count: 150

Registration Number: NCT02961790

Locations: 🇺🇸
Saint Elizabeth Medical Center South, Edgewood, Kentucky, United States
🇺🇸
Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States
🇺🇸
Saint Vincent Hospital -Green Bay, Green Bay, Wisconsin, United States

and more 10 locations

Urinary Biomarkers in Overactive Bladder in Children

Not Applicable

Conditions: Overactive Bladder

Interventions: Drug: Oxybutynin

First Posted Date: 2016-03-09

Last Posted Date: 2016-03-10

Lead Sponsor: Children's Hospital Zagreb

Target Recruit Count: 50

Registration Number: NCT02704013

Locations: 🇭🇷
Children's Hospital Zagreb, Zagreb, Croatia

Minirin Versus Oxybutynin for Nocturnal Enuresis in Children

Phase 3

Completed

Conditions: Nocturnal Enuresis

Interventions: Drug: Minirin
Drug: Oxybutynin

First Posted Date: 2015-09-02

Last Posted Date: 2015-09-02

Lead Sponsor: Hormozgan University of Medical Sciences

Target Recruit Count: 66

Registration Number: NCT02538302

Locations: 🇮🇷
Shahid Mohammadi hospital, Bandar Abbas, Hormozgan, Iran, Islamic Republic of

Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Pain in the Pediatric Population

Not Applicable

Conditions: Disorder of Urinary Stent

Interventions: Drug: Oxybutynin
Drug: Tamsulosin

First Posted Date: 2015-06-29

Last Posted Date: 2015-06-29

Lead Sponsor: Phoenix Children's Hospital

Target Recruit Count: 60

Registration Number: NCT02483793

A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment

Phase 2

Completed

Conditions: Overactive Bladder
Mild Cognitive Impairment

Interventions: Drug: fesoterodine 4mg
Drug: Oxybutynin
Drug: placebo
Drug: fesoterodine 8mg

First Posted Date: 2014-09-15

Last Posted Date: 2020-02-19

Lead Sponsor: University of Alberta

Target Recruit Count: 47

Registration Number: NCT02240459

Locations: 🇨🇦
Division of Geriatric Medicine, Clinical Sciences Building, University of Alberta Hosp, Edmonton, Alberta, Canada

Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis

Phase 3

Withdrawn

Conditions: Hyperhidrosis

Interventions: Drug: Placebo
Drug: Oxybutynin

First Posted Date: 2014-03-31

Last Posted Date: 2016-07-26

Lead Sponsor: Cristália Produtos Químicos Farmacêuticos Ltda.

Registration Number: NCT02099695

Locations: 🇧🇷
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
🇧🇷
Hospital Israelita Albert Einstein, São Paulo, Brazil

Long Term Results of the Use of Oxybutynin for the Treatment of Hyperhidrosis

Completed

Conditions: Hyperhidrosis

Interventions: Drug: Oxybutynin

First Posted Date: 2013-10-08

Last Posted Date: 2013-10-08

Lead Sponsor: Hospital Israelita Albert Einstein

Target Recruit Count: 1100

Registration Number: NCT01956591

Locations: 🇧🇷
Hospital Israelita Albert Einstein, São Paulo, Brazil

Efficacy of a Combined Surgical and Pharmacological Therapy to Treat Mixed Urinary Incontinence.

Phase 4

Completed

Conditions: Urinary Incontinence Mixed (Stress and Urge)

Interventions: Procedure: TVT-O/Oxytrol
Device: TVT-O
Drug: Oxytrol

First Posted Date: 2013-07-15

Last Posted Date: 2013-07-15

Lead Sponsor: Jewish General Hospital

Target Recruit Count: 66

Registration Number: NCT01899794

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy